发明授权
EP1854477B1 Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.
有权
血浆激肽释放的肽抑制剂用于眼科疾病的治疗中使用
- 专利标题： Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.
- 专利标题（中）： 血浆激肽释放的肽抑制剂用于眼科疾病的治疗中使用
-
申请号： EP07005182.6申请日： 2007-03-13
-
公开(公告)号： EP1854477B1公开(公告)日： 2016-08-03
- 发明人: Belichard, Pierre
- 申请人： Dyax Corp.
- 申请人地址： 55 Network Drive Burlington, MA 01803 US
- 专利权人： Dyax Corp.
- 当前专利权人： Dyax Corp.
- 当前专利权人地址： 55 Network Drive Burlington, MA 01803 US
- 代理机构： Potter Clarkson LLP
- 优先权： EP06360008 20060316; EP06291516 20060926
- 主分类号： A61K38/55
- IPC分类号： A61K38/55 ; A61P27/02
摘要：
The present invention relates to compositions and methods for treating ophthalmic disorders of humans or animals. The present compositions and methods are highly suitable for intraocular administration into the interior of an eye and provide therapeutic effects to the eye as they are effective in stabilizing, enhancing and/or improving a patient's vision. More specifically, the present invention relates to compositions and methods for treating ophthalmic diseases or disorders with exudative, hemorrhagic and/or inflammatory conditions. Even more specifically, the present invention relates to compositions and methods for treating retinal diseases or disorders, and more specifically ophthalmic diseases or disorders related to impaired retinal vessel permeability and/or integrity.
公开/授权文献
信息查询
IPC分类:
